Quantum-Si Q1 net loss widens to $21.7M; Proteus sequencing milestones on track

Quantum-Si Inc

2026-Q1 EPS reported -$0.10 revenue$258,000

Revenue of $258,000, gross margin 29%; net loss $21.7M vs $19.2M YoY.
Adjusted EBITDA negative $20.1M; adjusted operating expenses $21.4M.
Achieved automated sequencing runs on integrated Proteus instruments.
Current kit detects 17 amino acids; first customer samples sequenced on prototype.
Anticipates commercial launch end of 2026; early access sites this summer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Quantum-Si Inc reported the first quarter ended March 31, 2026 results: revenue $258,000, net income $21.7 million.

Period: the first quarter ended March 31, 2026
Revenue: $258,000
Net income: $21.7 million
Result: reported results

Exact text from the filing

For the first quarter of 2026, the Company recorded revenue of $258,000. Gross profit was $74,000 and gross margin was 29%. Total operating expenses were $24.1 million in the first quarter of 2026, compared to $25.6 million for the same period in the prior year. Adjusted total operating expenses were $21.4 million in the first quarter of 2026 compared to $22.9 million for the same period in the prior year.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Quantum-Si Inc filing history →

Source: SEC EDGAR

accession 0001816431-26-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.